Company Analysis

Karyopharm Therapeutics Inc. (KPTI)

Nasdaq: KPTI · Pharmaceutical Preparations · Newton, MA · filing with the SEC since 2010
Grade3.8
◀ Past 3.7● Present 3.6▶ Future 4.3
1 est.

Who runs Karyopharm Therapeutics Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Paulson Richard A.
President and CEO. First filing Feb 2020, latest May 15, 2026, 42 filings in all.
Officers reporting now
7
of 13 people with a filing in the last fifteen months
Directors reporting now
6
33 people on the record since 2013
Officerssales are open-market, Oct 19, 2025 to Oct 19, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Abate KristinChief Accounting OfficerNov 2024Oct 19, 20267 · $0.00
Poulton StuartEVP, Chief Development OfficerAug 2022Jul 30, 20264 · $100,000
Paulson Richard A.President and CEOFeb 2020May 15, 20262 · $100,000
Cheng Sohanya RoshanEVP & Chief Commercial OfficerJun 2021May 15, 20262 · $0.00
Rangwala ReshmaEVP & Chief Medical OfficerApr 2022May 15, 20263 · $100,000
Mano MichaelEVP, CLO&SecretaryJan 2021May 15, 20262 · $0.00
Macomber LoriEVP, CFO & TreasurerJan 2025Feb 4, 20261 · $0.00
Directorssales are open-market, Oct 19, 2025 to Oct 19, 2026
NameRoleFirst filingLatest filingSales, 12 months
Bohlin Garen GdirectorNov 2013May 26, 2026none
Greene Barry EdirectorNov 2013May 26, 2026none
Oliger Christy J.directorAug 2020May 26, 2026none
Pakianathan DeepikadirectorNov 2013May 26, 2026none
Schor ChendirectorNov 2020May 26, 2026none
Su ZhendirectorSep 2023May 26, 2026none
Earlier names on the record25, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton KPTI · research, not advice